Literature DB >> 11114633

Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma.

T J Musholt1, P B Musholt, N Khaladj, D Schulz, G F Scheumann, J Klempnauer.   

Abstract

BACKGROUND: The expression of RET/PTC chimeras was demonstrated in 10% to 20% of sporadic papillary thyroid carcinomas (PTCs), whereas rearrangements of NTRK1 were detected less frequently. Some investigators have hypothesized that RET/PTC activation is preferentially associated with slow-growing tumors of low malignancy in elderly patients; other studies support the contrary.
METHODS: Expression analysis of RET and NTRK1 was performed by duplex reverse transcription-polymerase chain reaction in tumor tissues from 119 patients with PTC. Samples with suspected rearrangements were further analyzed for the expression of the hybrid messenger RNAs RET/PTC 1 to RET/PTC 7 and for known NTRK1 chimeras, respectively.
RESULTS: Seventeen of 119 tumors (14.3%) revealed somatic rearrangements of RET; NTRK1-derived hybrids were demonstrated in 15 cases (12.6%). In patients with RET/PTC chimeras, a statistically not significant tendency towards younger age, lower recurrence rate, and improved survival was observed, despite increased incidence of lymph node metastasis. Cumulative survival analysis of NTRK1 rearrangement-positive individuals demonstrated a worse outcome when compared with patients with expression of RET hybrids (P =.055).
CONCLUSIONS: The high incidence of yet uncharacterized NTRK1 hybrid mRNAs in our patient cohort leads to the speculation that activating chromosomal rearrangements of several tyrosine kinase receptors may be a common feature of PTCs and that the expression of distinct chimeras may potentially be of prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114633     DOI: 10.1067/msy.2000.110845

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  27 in total

1.  Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis.

Authors:  Jennifer L Hunt; Zubair W Baloch; Leon Barnes; Patricia A Swalsky; Cindy L Trusky; E Sesatomi; Sydney Finkelstein; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

2.  Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.

Authors:  Thomas J Musholt; Sonja Schönefeld; Christina H Schwarz; Felix M Watzka; Petra B Musholt; Christian Fottner; Matthias M Weber; Erik Springer; Arno Schad
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

3.  Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.

Authors:  Jie Ming; Zeming Liu; Wen Zeng; Yusufu Maimaiti; Yawen Guo; Xiu Nie; Chen Chen; Xiangwang Zhao; Lan Shi; Chunping Liu; Tao Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 4.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

5.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

Review 6.  Molecular analysis of thyroid tumors.

Authors:  Feriyl Bhaijee; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

7.  Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules.

Authors:  Thomas J Musholt; Christian Fottner; Matthias M Weber; Waltraud Eichhorn; Joachim Pohlenz; Petra B Musholt; Erik Springer; Arno Schad
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

8.  High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.

Authors:  Ying C Henderson; Thomas D Shellenberger; Michelle D Williams; Adel K El-Naggar; Mitchell J Fredrick; Kathleen M Cieply; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Frequency of close positioning of chromosomal loci detected by FRET correlates with their participation in carcinogenic rearrangements in human cells.

Authors:  Manoj Gandhi; Viktoria Evdokimova; Yuri E Nikiforov
Journal:  Genes Chromosomes Cancer       Date:  2012-08-10       Impact factor: 5.006

10.  Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.

Authors:  Petra B Musholt; Thomas J Musholt; Saskia C Morgenstern; Karl Worm; Sien-Yi Sheu; Kurt W Schmid
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.